Mediport use as an acceptable standard for CAR T cell infusion.

ABSTRACT:

Introduction

Mediport use as a clinical option for the administration of chimeric antigen receptor T cell (CAR T cell) therapy in patients with B-cell malignancies has yet to be standardized. Concern for mediport dislodgement, cell infiltration, and ineffective therapy delivery to systemic circulation has resulted in variable practice with intravenous administration of CAR T cell therapy. With CAR T cell commercialization, it is important to establish practice standards for CAR T cell delivery. We conducted a study to establish usage patterns of mediports in the clinical setting and provide a standard of care recommendation for mediport use as an acceptable form of access for CAR T cell infusions.

Methods

In this retrospective cohort study, data on mediport use and infiltrat

SUBMITTER: Eylon M 

PROVIDER: S-EPMC10642031 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature